{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T09:11:57Z","timestamp":1721034717569},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T00:00:00Z","timestamp":1378944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s13730-013-0097-7","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T12:11:38Z","timestamp":1378901498000},"page":"110-117","source":"Crossref","is-referenced-by-count":3,"title":["Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies"],"prefix":"10.1007","volume":"3","author":[{"given":"Tomohiro","family":"Udagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaeko","family":"Motoyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Ariji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisaku","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Chiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Morio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuki","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"issue":"17","key":"97_CR1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387.","journal-title":"N Engl J Med"},{"key":"97_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/asheducation-2011.1.15","volume":"2011","author":"D Kavanagh","year":"2011","unstructured":"Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program. 2011;2011:15\u201320.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"97_CR3","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21:2180\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"97_CR4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","volume":"24","author":"G Ariceta","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24:687\u201396.","journal-title":"Pediatr Nephrol"},{"key":"97_CR5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","volume":"360","author":"RA Gruppo","year":"2009","unstructured":"Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360:544\u20136.","journal-title":"N Engl J Med"},{"key":"97_CR6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","volume":"360","author":"J N\u00fcrnberger","year":"2009","unstructured":"N\u00fcrnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360:542\u20134.","journal-title":"N Engl J Med"},{"key":"97_CR7","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","volume":"362","author":"LB Zimmerhackl","year":"2010","unstructured":"Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med. 2010;362:1746\u20138.","journal-title":"N Engl J Med"},{"key":"97_CR8","doi-asserted-by":"crossref","first-page":"197A","DOI":"10.1681\/ASN.2010121293","volume":"22","author":"C Licht","year":"2011","unstructured":"Licht C, Muus P, Legendre CM, et al. Phase II study of eculizumab (ECU) in patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange\/infusion. J Am Soc Nephrol. 2011;22:197A TH-PO366.","journal-title":"J Am Soc Nephrol"},{"key":"97_CR9","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01193348 . Accessed 7 Sep 2013"},{"key":"97_CR10","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1542\/peds.2012-1466","volume":"131","author":"T Honda","year":"2013","unstructured":"Honda T, Ogata S, Mineo E, et al. A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin \u03b1. Pediatrics. 2013;131:e928\u201333.","journal-title":"Pediatrics"},{"key":"97_CR11","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","volume":"23","author":"C Loirat","year":"2008","unstructured":"Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008;23:1957\u201372.","journal-title":"Pediatr Nephrol"},{"key":"97_CR12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0030-1262885","volume":"36","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Blanc C, Garnier A, et al. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin Thromb Hemost. 2010;36:633\u201340.","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"97_CR13","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","volume":"4","author":"CJ Mache","year":"2009","unstructured":"Mache CJ, Acham-Roschitz B, Fr\u00e9meaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(8):1312\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"97_CR14","doi-asserted-by":"crossref","first-page":"e1385","DOI":"10.1542\/peds.2011-1685","volume":"130","author":"M Giordano","year":"2012","unstructured":"Giordano M, Castellano G, Messina G, et al. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics. 2012;130:e1385\u20138.","journal-title":"Pediatrics"},{"key":"97_CR15","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00467-011-1989-4","volume":"26","author":"S Tschumi","year":"2011","unstructured":"Tschumi S, Gugger M, Bucher BS, et al. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol. 2011;26:2085\u20138.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"97_CR16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","volume":"66","author":"BH Lee","year":"2009","unstructured":"Lee BH, Kwak SH, Shin JI, et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency. Pediatr Res. 2009;66(3):336\u201340.","journal-title":"Pediatr Res"},{"issue":"26","key":"97_CR17","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"AL Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364(26):2561\u20133.","journal-title":"N Engl J Med"},{"issue":"1","key":"97_CR18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","volume":"93","author":"Y Kanakura","year":"2011","unstructured":"Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93(1):36\u201346.","journal-title":"Int J Hematol"},{"key":"97_CR19","first-page":"45","volume":"3","author":"M Ohanian","year":"2011","unstructured":"Ohanian M, Cable C, Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol. 2011;3:45\u201350.","journal-title":"Clin Pharmacol"},{"key":"97_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","volume":"5","author":"H Saito","year":"2007","unstructured":"Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31\u201341.","journal-title":"J Thromb Haemost"},{"key":"97_CR21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1172\/JCI22782","volume":"115","author":"K Abeyama","year":"2005","unstructured":"Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115:1267\u201374.","journal-title":"J Clin Invest"},{"key":"97_CR22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1046\/j.1523-1755.2002.00160.x","volume":"61","author":"H Ikeguchi","year":"2002","unstructured":"Ikeguchi H, Maruyama S, Morita Y, et al. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int. 2002;61:490\u2013501.","journal-title":"Kidney Int"},{"issue":"10","key":"97_CR23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ajh.22137","volume":"86","author":"C Ohwada","year":"2011","unstructured":"Ohwada C, Takeuchi M, Kawaguchi T, et al. Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome\/hepatic veno-occlusive disease after bone marrow transplantation. Am J Hematol. 2011;86(10):886\u20138.","journal-title":"Am J Hematol"},{"issue":"8","key":"97_CR24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3899\/jrheum.111137","volume":"39","author":"K Tonooka","year":"2012","unstructured":"Tonooka K, Ito H, Shibata T, et al. Recombinant human soluble thrombomodulin for treatment of thrombotic microangiopathy associated with lupus nephritis. J Rheumatol. 2012;39(8):1766\u20137.","journal-title":"J Rheumatol"},{"key":"97_CR25","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1016\/j.thromres.2010.06.024","volume":"126","author":"M Sakai","year":"2010","unstructured":"Sakai M, Ikezoe T, Bandobashi K, et al. Successful treatment of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with recombinant human soluble thrombomodulin. Thromb Res. 2010;126:e392\u20133.","journal-title":"Thromb Res"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-013-0097-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-013-0097-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-013-0097-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T16:44:57Z","timestamp":1559493897000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-013-0097-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1007\/s13730-013-0097-7","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,12]]}}}